Merck (MRK) Net Income - Minority (2009 - 2012)
Merck (MRK) reported Net Income - Minority of -$2.4 billion for Q4 2012, down 0.7% year-over-year from -$2.5 billion in Q1 2012, and down 0.7% quarter-over-quarter from -$2.4 billion in Q4 2011.
Merck (MRK) Net Income - Minority (2009 - 2012) Analysis & Trends
Merck (MRK) has 4 years of Net Income - Minority data on file, last reported at -$2.4 billion in Q4 2012.
- Net Income - Minority for Q4 2012 came in at -$2.4 billion, down 0.7% year-over-year; the trailing twelve-month figure through Dec 2012 was -$2.4 billion (down 0.7% YoY), and the FY2012 annual result was -$2.4 billion, down 0.7% from the prior year.
- Net Income - Minority eased to -$2.4 billion in Q4 2012 per MRK's latest filing, from -$2.4 billion in the prior quarter.
- Over five years, Net Income - Minority peaked at -$2.4 billion in Q4 2011 and troughed at -$2.5 billion in Q1 2010.
- A 4-year average of -$2.4 billion and a median of -$2.4 billion in 2010 frame the typical range for Net Income - Minority.
- The sharpest annual moves came in 2011 and 2012: Net Income - Minority advanced 0.41% in 2011, then retreated 0.7% in 2012.
- A 4-year view of Net Income - Minority shows it stood at -$2.4 billion in 2009, then dropped by 0.08% to -$2.4 billion in 2010, then gained by 0.12% to -$2.4 billion in 2011, then declined by 0.7% to -$2.4 billion in 2012.
- Business Quant data shows MRK's Net Income - Minority at -$2.4 billion in Q4 2012, -$2.4 billion in Q4 2011, and -$2.5 billion in Q1 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | - |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -2.44 Bn |
| Dec 31, 2011 | -2.43 Bn |
| Mar 31, 2011 | -2.46 Bn |
| Dec 31, 2010 | -2.43 Bn |
| Sep 30, 2010 | -2.46 Bn |
| Jun 30, 2010 | -2.43 Bn |
| Mar 31, 2010 | -2.47 Bn |
| Dec 31, 2009 | -2.43 Bn |